Definium Therapeutics, Inc.
Definium Therapeutics, Inc.
- Market cap
- $3.99B
Your view on DFTX
Overview
What the company does, where it operates, and who runs it.
About Definium Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert Barrow
- Headquarters
- One World Trade Center, New York, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert Barrow
- Headquarters
- One World Trade Center, New York, NY, US
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.
Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).
Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Definium Therapeutics, Inc.. Starting points for Definium Therapeutics, Inc.: EPS -$2.48, beta 2.21 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Definium Therapeutics, Inc.. Trailing twelve-month EPS for Definium Therapeutics, Inc. stands at -$2.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Definium Therapeutics, Inc.. Definium Therapeutics, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $236,124 | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||
| PRAXPraxis Precision Medicines, Inc. | Healthcare | NASDAQ | $8.5B | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Definium Therapeutics, Inc., and how their positions are changing. At a $3.99B market value, institutional positions materially move Definium Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Definium Therapeutics, Inc. executives and directors. Shares of Definium Therapeutics, Inc. have traded between $12.88 and $49.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Definium Therapeutics, Inc.. Coverage tracks Definium Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Definium Therapeutics, Inc.